# OnCo record clio-8221 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/clio-8221/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "clio-8221" ;
  schema:name "CLIO-8221"@en ;
  schema:description "CLIO-8221 is an experimental dual-payload antibody-drug conjugate from Callio Therapeutics, in phase 1 trials for HER2-expressing advanced solid tumours and metastatic breast cancer."@en ;
  schema:url <https://onco.cc/drugs/clio-8221/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://calliotx.com/>, <https://www.biospace.com/press-releases/callio-therapeutics-to-present-phase-1-trial-design-of-clio-8221-novel-dual-payload-adc-at-asco-2026>, <https://www.biospace.com/press-releases/callio-therapeutics-to-present-phase-1-trial-design-of-clio-8221-novel-dual-payload-adc-at-asco-2026>, <https://clinicaltrials.gov/study/NCT07300943>, <https://clinicaltrials.gov/search?intr=CLIO-8221> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Dual-payload antibody-drug conjugate" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/callio-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07300943/> .